Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

NCT07104331 is registered in ClinicalTrials.gov with Sarcoma Alliance for Research through Collaboration as lead sponsor.

NCT NCT07104331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Phase
Phase 2
Overall status
Recruiting
Start date
February 24, 2026
Completion date
August 30, 2029
Enrollment
41 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

epithelioid hemangioendothelioma (ehe)